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A new benz[a]anthracene derivative called mayamycin (1) was identified in cultures of Streptomyces sp. strain HB202,
which was isolated from the marine sponge Halichondria panicea and selected because of its profound antibiotic activity.
The ability to produce aromatic polyketides was indicated by genetic analyses, demonstrating the presence of a type II
polyketide synthase. The production of mayamycin (1) was induced by variation of the culture conditions. The structure
of 1 was elucidated by HPLC-UV/MS and NMR spectroscopy. Mayamycin (1) exhibited potent cytotoxic activity against
eight human cancer cell lines and showed activity against several bacteria including antibiotic-resistant strains.
Marine actinomycetes are among the most promising natural
producers of new antibiotics with clinical relevance.1 Therefore,
we have performed a systematic analysis of Actinobacteria isolated
from marine habitats with regard to their potential to produce
biologically active natural products.2 This strategy included the
selection of promising producers based on bioassay-guided analyses
and the detection of genes encoding for the biosynthesis of
secondary metabolites. Within such an approach, the marine
Streptomyces sp. strain HB202, which was isolated from the sponge
Halichondria panicea, showed a wide antibiotic activity spectrum
while also containing one type II polyketide synthase gene fragment
with a similarity of 92% to the jadomycin polyketide ketosynthase
gene from Streptomyces Venezuelae ISP5230 (AAB36562).3 Even
though many different cultivation experiments were conducted with
this strain, stimulation with subinhibitory concentrations of antibiot-
ics was demonstrated,4 and no aromatic polyketide was observed.
The aim of our study was to demonstrate that by further varying
the cultivation conditions, strain HB202 has the ability to biosyn-
thesize a type II PKS product.
Previous investigations had demonstrated the production of
streptophenazines A-H by Streptomyces sp. strain HB202. In this
former study, the biosynthesis was induced by subinhibitory
concentrations of the antibiotics bacitracin and tetracycline,4 but
no secondary metabolite consistent with the identified iterative PKS
gene fragment was observed. To promote the production of
additional substances, especially aromatic polyketides, different
cultivation conditions were applied, and under one of these applied
conditions only one compound, an aromatic polyketide, was
produced, which is described here as mayamycin (1).
Cultivation of the bacterium in penicillin flasks containing
GYM medium without using shaking conditions led to the
production of the new benz[a]anthracene derivative mayamycin
(1). No further compounds were observed under these conditions.
The culture broth and cells were homogenized and extracted with
EtOAc. The extract was separated by preparative reversed-phase
(C18) HPLC to yield 1.
Mayamycin (1) was an amorphous, brown solid with a molecular
formula of C26H25NO7, as determined by HRESIMS (m/z 464.1707
[M + H]+) and verified by 13C NMR and 1H-13C HMBC spectra.
According to its UV-vis spectrum, metabolite 1 was likely to
belong to the anthraquinone group. This was supported by a set of
downfield resonances occurring in the 13C NMR spectrum between
δ 100 and 170 ppm, which belonged to aromatic carbon atoms,
and by two carbonyl resonances that were observed at δ 194.2 and
188.0 ppm, consistent with a quinone skeleton. According to their
chemical shifts, three of the aromatic carbon atoms mentioned above
(δ 154.4, 156.5, and 162.9 ppm) carried hydroxy groups. In
addition, one methyl residue (2.45, s) attached at C-3 to the aromatic
carbon skeleton was observed. Comprehensive analyses of 2D NMR
(1H-1H COSY, HSQC, 1H-13C HMBC, and NOESY) data showed
that compound 1 was an angucycline-type polyketide with a
C-glycosidically bound amino sugar. The aromatic protons H-9,
H-10, and H-11 were located at the D-ring of the angucycline
skeleton and showed HMBC couplings to the remaining carbons
(C-7a, C-8, and C11a) of ring D as well as to the carbonyl carbon
C-12 of the C-ring (Figure 1). Additionally, 1H-1H COSY
correlations were observed from H-9 to H-10 and from H-10 to
H-11. The remaining two aromatic protons together with the methyl
group were found to be located at ring A. Long-range H,C-couplings
revealed their exact position at this ring (C-2, C-4, and C-3,
respectively) (Figure 1). This angucyclinone skeleton of 1 is
identical to the known dehydrorabelomycin.5
Pivotal correlations that proved the connection site of the amino
sugar at C-5 were the long-range H,C-couplings of H-4 to C-5 and
C-12b as well as the couplings of H-1′ to C-4a, C-5, and C-6. A
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Figure 1. 2D NMR correlations of mayamycin (1) relevant for the
structure elucidation: (a) HMBC couplings; (b) NOESY correlations.
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NOESY correlation between H-4 and H-1′ and the chemical shift
of C-1′ (δ 72.8 ppm) confirmed that the amino sugar is attached to
the benz[a]anthracene skeleton of 1 by a C-glycosidic bond.
Further evaluation of the NMR data showed the amino sugar to
be a 2,3,6-trideoxy-3-methylaminopyran. The position of the
methylamino residue was evident from the long-range H,C-
couplings between the N-CH3 and C-3′ as well as NOESY
correlations between the N-CH3 and both protons at C-2′. The rest
of the structure of the sugar moiety was revealed by long-range
H,C-couplings of both protons at H-2′ with C-1′, C-3′, and C-4′,
of H-4′ with C-3′, C-5′, and 5′-CH3, and of H-5′ with C-3′, C-4′,
and 5′-CH3. The methyl group at C-5′ showed HMBC couplings
with C-4′ and C-5′. Additionally, a series of 1H-1H COSY as well
as NOESY correlations were observed for the sugar moiety from
H-1′ to H-2′a and H-2′b, from H-2′ to H-3′, from H-3′ to H-4′, and
from H-4′ to H-5′. The methyl group at C-5′ showed NOESY
correlations to H-5′ as well as to H-4′. The chemical shift of C-4′
(74.5 ppm) in combination with the molecular formula of the
compound indicated a free hydroxy group at this position. The 3J-
coupling constants of 9.0 Hz for H-5′/H-4′ as well as for H-4′/H-
3′ showed axial orientations for these protons. The likewise axial
orientation of H-1′ was inferred from the NOE interaction H-3′/
H-1′. These results indicate the sugar is N-demethylangolosamine,
and a relative configuration of (1′R*,3′R*,4′S*,5′R*) is assigned
to mayamycin (1). Angolosamine, which has a dimethylamino
group, is present in benzanthrins A and B, related compounds that
have the same angucyclinone core.6 Although the absolute con-
figuration has not been determined, the glycoside has been depicted
in the D-configuration because in other cases where the configuration
of angolosamine has been established D-angolosamine has been
present.7,8
Most of the reported angucyclines are O-deoxyglycosides, and
a much smaller group are C-glycosides.9 In the case of mayamycin
(1) the sugar binding site is C-5. At this position so far, no
C-glycosidic bound sugar is known, although some examples exist
with S- or O-glycosidic bound sugars.10,11 Deoxyaminosugars are
quite frequently found in antibiotics. Examples with D-angolosamine
are angolamycin7 and medermycin.8 In our case the aminosugar is
the mono N-demethylated form of angolosamine. Other examples
of angucyclines with an aminosugar are the antibiotic P371A12 and
the marmycins.9
With regard to the combination of the angucyclinone core
structure with this particular aminosugar and the site of glycosy-
lation as well as the character of the glycosylation (C-glycosidic
bond) mayamycin (1) is unusual compared to previously reported
angucycline amino glycoside metabolites.
Members of the angucycline class are polyketide-derived tetra-
cyclic benz[a]anthraquinones that exhibit a wide range of biological
activities including antibacterial, enzyme-inhibitory, and cytostatic
effects.13 In a previous bioassay-guided approach it was shown that
the extract of strain HB202 inhibited the growth of various Gram-
positive and Gram-negative bacteria (data not shown). Therefore,
the antimicrobial activity of mayamycin (1) was analyzed using a
wide range of Gram-positive and Gram-negative bacteria and yeast
strains. The results revealed strong inhibitory activity against several
test strains, including clinically relevant bacteria, such as Pseudomo-
nas aeruginosa and methicillin-resistant Staphylococcus aureus
(MRSA), the causative agents of acne vulgaris, Propionibacterium
acnes, the human skin flora forming bacteria Dermabacter hominis
and BreVibacterium epidermidis, and the phytopathogenic bacterium
Xanthomonas campestris, as summarized in Table 2. On the other
hand, 1 was found to be inactive against the yeast Candida glabrata
and the fungus Septoria tritici as well as the Gram-negative bacteria
Escherichia coli, Pseudomonas syringae, and Ralstonia solan-
acearum. In addition, 1 showed an inhibitory activity against the
phytopathogenic oomycete Phytophthora infestans, with an IC50
value of 15.2 µM (positive control: cycloheximid, IC50 0.36 µM)
in a growth-inhibitory assay.
Furthermore, mayamycin (1) showed potent in Vitro cytotoxicity
against eight human cancer cell lines (Table 3). The determined
IC50 values were within a concentration range of 0.13 to 0.33 µM.
Mayamycin (1) was also cytotoxic toward the mouse fibroblast cell
line NIH-3T3. The IC50 value of 1 was 0.22 µM. Tamoxifen was
used as positive control and showed an IC50 value of 23.7 µM.
Experimental Section
General Experimental Procedures. The optical rotation was
measured on a Perkin-Elmer model 241. The UV spectra were obtained
on a NanoVue (GE Healthcare). NMR spectra were recorded on a
Table 1. NMR Spectroscopic Data (600 MHz, CD3OD) for Mayamycin (1)
position δC, mult. δH (J in Hz) COSY HMBC NOESY
1 156.5, C
2 114.7, CH 6.74, s 4, 3-CH3, 12b
3 143.4, C
3-CH3 22.6, CH3 2.45, s 2, 3, 4 4
4 117.6, CH 8.00, s 2, 3-CH3, 4a, 5, 12b 3-CH3, 1′
4a 139.9, C
5 126.5, Cb
6 154.4, Cb
6a 138.4/119.4, C
7 194.2, C
7a 116.3, C
8 162.9, C
9 124.9, CH 7.29, dd (1.2, 8.5)a 10 7a, 11 10
10 138.8, CH 7.75, dd (7.5, 8.5)a 9, 11 8, 11, 11a 9, 11
11 120.4, CH 7.58, dd (1.2, 7.5)a 10 7a, 9, 12 10
11a 137.9, C
12 188.0, Cb
12a 119.4/138.4, C
12b 117.8, C
1′ 72.8, CH 5.70, dd (11.7, 2.0) 2′a, 2′b 4a, 5, 6 4, 2′a, 2′b, 3′, 5′
2′a 32.9, CH2 2.35, ddd (13.0, 11.7) 1′, 3′ 1′, 3′, 4′ 1′, 3′, 3′-N-CH3
2′b 32.9, CH2 2.27, ddd (13.0, 2.0, 4.8) 1′, 3′ 1′, 3′, 4′ 1′, 3′, 3′-N-CH3
3′ 63.0, CH 3.23, br ddd (4.8, 11.7, 9.0) 2′, 4′ 1′, 2′a, 2′b, 3′-N-CH3
3′-N-CH3 31.4, CH3 2.63, s 3′ 2′a, 2′b, 3′, 4′
4′ 74.5, CH 3.41, t (9.0) 3′, 5′ 3′, 5′, 5′-CH3 2′a, 3′, 3′-N-CH3, 5′, 5′-CH3
5′ 79.2, CH 3.56, dq (9.0, 6.1) 4′, 5′- CH3 3′, 4′, 5′-CH3 1′, 4′, 5′-CH3
5′-CH3 18.7, CH3 1.42, d (6.1) 5′ 4′, 5′ 4′, 5′
a J values were defined in CD2Cl2 because of broad 1H signals in CD3OD. b Deduced by HMBC correlations.
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Bruker AV600 spectrometer (600 and 150 MHz for 1H and 13C NMR,
respectively), using the signals of the residual solvent protons and the
solvent carbons as internal references (δH 3.31 and δC 49.0 ppm for
MeOH-d4). High-resolution mass spectra were acquired on a benchtop
time-of-flight spectrometer (MicrOTOF, Bruker Daltonics) with positive
electrospray ionization. Reversed-phase HPLC-UV/MS analysis was
performed using a C18 column (Phenomenex Onyx Monolithic C18,
100 × 3.00 mm) applying an H2O (A)/MeCN (B) gradient with 0.1%
HCOOH added to both solvents (gradient: 0 min 5% B, 4 min 60% B,
6 min 100% B; flow 2 mL/min) on a VWR Hitachi Elite LaChrom
system coupled to an ESI-ion trap detector (Esquire 4000, Bruker
Daltonics). Mayamycin (1) was detected at 3.0-3.4 min.
Isolation and Identification of Streptomyces sp. HB202. The
isolation and identification of strain HB202 was described by Mitova
et al.4 The strain was isolated from the marine sponge Halichondria
panicea collected from the Baltic Sea. The most closely related type
strains according to the 16S rRNA gene sequence (1473 bp) were
Streptomyces mediolani LMG 20093T (GenBank/EMBL/DDBJ acc. no.
AJ781354) with a sequence similarity of 99.9% and Streptomyces
griseus ATCC 51928T (GenBank/EMBL/DDBJ acc. no. AF112160)
with a sequence similarity of 99.8%.
Detection of Polyketide Synthase Gene Fragments. The PCR
approach for the detection of a type II polyketide synthase KSR domain
was performed according to Metsa¨-Ketela¨ et al.14 Sequencing of PCR
products was performed using a standard protocol.15 Comparison of
KSR gene fragments (505 nucleotides) of the marine Streptomyces sp.
HB202 was accomplished with sequences in the EMBL nucleotide
database available online at the European Bioinformatics Institute
homepage using the Basic Local Alignment Search Tool (blastx).16
One of the most closely related sequences was the jadomycin polyketide
ketosynthase gene of Streptomyces Venezuelae ISP5230 (92% similarity;
AAB36562).3
Cultivation. Cultivation conditions using 500 mL of GYM medium
(2 g of glucose, 2 g of yeast extract, 2 g of malt extract, 1 g of CaCO3,
500 mL of water, pH 7.2) in penicillin flasks were the only conditions
applied in this study that produced compound 1. After 7 days a 20 mL
sample was extracted with 10 mL of EtOAc. After evaporation of the
solvent the extract was redissolved in 200 µL of MeOH. An aliquot of
15 µL was analyzed by HPLC/UV-MS.
Additional cultivation approaches were performed, but no production
of 1 was observed under any of the following conditions: Erlenmeyer
flasks in GYM, MB (37.4 g of Marine Broth, Difco), and TSB10
medium (3 g of BD trypticase soy broth (TSB), 10 g of NaCl, 1 L of
water, pH 7.2) in volumes of 1000, 300, and 25 mL, respectively, under
shaking conditions (120 rpm).
Fermentation. For chemical analyses strain Streptomyces sp. HB202
was grown in GYM medium for 7 days at 28 °C in multiple 4 L
penicillin flasks. Each flask was inoculated with a 3 × 5 cm piece
from a GYM agar plate with a 4-week-old culture.
Purification of Mayamycin (1). The culture broth (5 L) was
homogenized by Ultra Turrax T25 basic (IKA-Werke GmbH and Co.,
Staufen, Germany) at 16 000 rpm for 30 s and extracted with 3.5 L of
EtOAc. Evaporation of the solvent yielded 400 mg of extract. An aliquot
was analyzed with HPLC-MS. The extract was subjected to preparative
HPLC (Phenomenex Gemini-NX C18 110A, 100× 50.00 mm; eluents:
H2O (A), MeCN (B); gradient 0 min 10% B, 17 min 60% B, 22 min
100% B; flow 100 mL/min; UV detection at 236 nm. Mayamycin (166.5
mg) eluted at 8.4-9.0 min).
(1′R*,3′R*,4′S*,5′R*)-Mayamycin (1): dark brown, amorphous
solid; [R]20D 0 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 440 (2.44),
330 (2.78), 301sh (2.68), 230 (3.07); for 1D and 2D NMR data, see
Table 1 and SI; HRESIMS m/z 464.1707 [M + H]+ (calcd for
C26H26NO7, 464.1709).
Antibacterial Activities. Antimicrobial assays were performed using
Bacillus subtilis (DSM 347), BreVibacterium epidermidis (DSM 20660),
Dermabacter hominis (DSM 7083), Escherichia coli K12 (DSM 498),
Propionibacterium acnes (DSM 1897), Pseudomonas aeruginosa (DSM
50071), Pseudomonas syringae pv aptata (DSM 50252), Ralstonia
solanacearum (DSM 9544), Staphylococcus epidermidis (DSM 20044),
Staphylococcus lentus (DSM 6672), Xanthomonas campestris (DSM
2405), and the yeast Candida glabrata (DSM 6425) and Septoria tritici.
The assays were prepared by transferring 10 µL of a 2 mM methanolic
solution of the sample compounds into one well of a 96-well microtiter
plate and evaporating the solvent in a vacuum centrifuge. Overnight
cultures of the test organisms in tryptic soy broth were diluted to an
OD600 of 0.02-0.05, and 200 µL of the resulting suspension was added
to the wells. After incubating the microtiter plates for 14-16 h at 28
°C, in the case of Dermabacter hominis for 24 h at 37 °C, 10 µL of a
resazurin solution (0.2 mg mL-1 PBS) was added to each well and the
plate incubated at 28 °C for 1-2 h. For evaluation of the cell viability
the reduction of resazurin to resorufin was assessed by measuring the
intensity of fluorescence at 560Ex/590Em nm.17 The resulting values were
compared to a positive (50 mg of chloramphenicol or tetracycline for
bacteria; 50 mg of cycloheximide for Candida glabrata, Septoria tritici,
and Phytophtera infestans) and a negative control (no compound) on
the same plate. Propionibacterium acnes was grown anaerobically
(Anaerocult A mini, Merck) in PYG medium (modified DSMZ medium
104) at 37 °C for 48 h. The bacterial culture was diluted to an OD600
of 0.03, 200 µL of the inoculum was added to each well, and the
microtiter plate was incubated anaerobically at 37 °C for 48 h.
The assays against Phytophthora infestans were prepared by transfer-
ring 190 µL of a spore suspension with a concentration of 1 × 104
spores/mL into one well of a 96-well microtiter plate, respectively.
From a 10 mM DSMO stock solution of mayamycin, a dilution series
with PBS buffer was established down to 100 µM. Then 10 µL of this
solution was added into the assay. After incubating the microtiter plate
for 48 h at 20 °C in the dark, the absorption was measured at 600 nm.
As positive control, cycloheximide was used.
The antibacterial assays against the clinically relevant strains
Staphylococcus epidermidis (clinical isolate, Dr. S. Schubert), Staphy-
lococcus aureus (ATCC 12600), Staphylococcus aureus (ATCC 33593),
Klebsiella pneumoniae (ATCC 700603), and Pseudomonas aeruginosa
(ATCC 10145) were performed as described by Sahly et al., 2003.18
Table 2. Antibacterial Activity of Mayamycin (1) against
Bacterial Strains
bacterial strains IC50 (µM)
IC50 (µM)
of the standard
Bacillus subtilis (DSM 347)
standard: chloramphenicol
8.0 9.0
BreVibacterium epidermidis (DSM 20660)
standard: tetracycline
7.45 13.9
Dermabacter hominis (DSM 7083)
standard: tetracycline
8.4 1.2
Klebsiella pneumoniae
(ATCC 700603; ESBL)
2.5 n.d.a
Propionibacterium acnes (DSM 1897)
standard: chloramphenicol
31.2 1.0
Pseudomonas aeruginosa (DSM 50071)
standard: chloramphenicol
2.5 27.3
Staphylococcus aureus (ATCC 12600)
standard: moxifloxacin
2.5 7.5
Staphylococcus aureus
(ATCC 33593; MRSA)
1.25 n.d.a
Staphylococcus epidermidis
(DSM 20044)
0.31 n.d.a
Staphylococcus lentus (DSM 6672)
standard: chloramphenicol
8.0 2.3
Xanthomonas campestris (DSM 2405)
standard: chloramphenicol
30.0 3.6
a n.d. not determined.
Table 3. Cytotoxic Activity of Mayamycin (1) in Eight Human
Cancer Cell Lines
human cancer
cell line IC50 [µM]
IC50 [µM]
of the standard
HepG2 (hepatocellular carcinoma)
standard: tamoxifen
0.2 23.4
HT-29 (colon adenocarcinoma)
standard: tamoxifen
0.3 38.6
GXF251L (gastric cancer)
standard: adriamycin
0.2 <0.052
LXF529L (non-small-cell lung cancer)
standard: adriamycin
0.16 <0.052
MAXF401NL (mammary cancer)
standard: adriamycin
0.29 <0.052
MEXF462NL (melanoma cancer)
standard: adriamycin
0.13 <0.052
PAXF1657L (pancreatic cancer)
standard: adriamycin
0.15 <0.052
RXF486L (renal cancer)
standard: adriamycin
0.33 e0.052
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Cytotoxic Activities. The sensitivity of the cell lines NIH-3T3,
HepG2, and HT-29 to the isolated compound (1) was evaluated by
monitoring of the metabolic activity using the CellTiter-BlueCell
viability assay (Promega). The mouse fibroblast cell line was kindly
provided by G. Rimbach (University of Kiel, Germany). The human
hepatocellular carcinoma cell line HepG2 and the human colon
adenocarcinom cell line HT-29 were obtained from the German
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany). HepG2 and NIH-3T3 cells were maintained in RPMI 1640
medium, and HT-29 cells were cultured in Mc Coy’s 5A medium.
Media were supplemented with 10% fetal bovine serum (Promocell),
100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrogen). The
cultures were maintained at 37 °C under a humidified atmosphere and
5% CO2. The cell lines were transferred twice per week. For
experimental procedures, cells were seeded in 96-well plates at
concentrations of 7500 cells (NIH-3T3) and 10 000 cells (HepG2 and
HT-29) per well. After 24 h incubation the medium was removed, and
100 µL of the test sample adjusted to final concentrations ranging from
10 µM to 40 nM by dilution in growth medium was added to the cells.
Each concentration was tested in triplicate. Tamoxifen, as a standard
therapeutic drug, was used as positive control. Following sample
addition, plates were cultured for 24 h at 37 °C. Afterward, the assay
was performed according to the manufacturer’s instructions. Fluores-
cence was measured using the microplate reader Infinite M200 (Tecan)
at 560 nm excitation and 590 nm emission. IC50 values were calculated
using SigmaPlot software.
The in Vitro cytotoxic activities against the gastric cancer cell line
GXF 251 L cells, non-small-cell lung cancer cell line LXFL 529 L,
melanoma cancer cell line MEXF 462NL, mammary cancer cell line
MAXF 401NL, renal cancer cell line RXF 486 L, and pancreatic cancer
cell line PAXF1657L were determined by a modified propidium iodide
monolayer assay according to a described procedure by Oncotest
GmbH.19
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